BridgeBio Oncology Therapeutics, Inc.
BBOT
$11.38
$0.312.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -57.40% | -28.93% | 20.62% | ||
| Total Depreciation and Amortization | 0.00% | 235.19% | 0.00% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 1,714.81% | -48.52% | -69.87% | ||
| Change in Net Operating Assets | 56.16% | 206.93% | -149.41% | ||
| Cash from Operations | -23.50% | -18.85% | -181.69% | ||
| Capital Expenditure | 39.39% | -42.59% | 21.43% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | 312.31% | -36.45% | 102.00% | ||
| Cash from Investing | 320.74% | -37.28% | 102.00% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -100.00% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -100.00% | -- | -100.00% | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -145.59% | -708.42% | -- | ||
| Cash from Financing | 1,827.81% | 4,792.08% | -100.00% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 7,014.73% | 214.39% | -149.95% | ||